Immunocore Holdings Earnings Estimate
| IMCR Stock | USD 32.14 1.12 3.61% |
Immunocore |
Immunocore Holdings Earnings Estimation Breakdown
The calculation of Immunocore Holdings' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Immunocore Holdings is estimated to be -0.140575 with the future projection ranging from a low of -0.28725 to a high of 0.04825. Please be aware that this consensus of annual earnings estimates for Immunocore Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.29 Lowest | Expected EPS | 0.05 Highest |
Immunocore Holdings Earnings Projection Consensus
Suppose the current estimates of Immunocore Holdings' value are higher than the current market price of the Immunocore Holdings stock. In this case, investors may conclude that Immunocore Holdings is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Immunocore Holdings' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 15 | 46.63% | 0.17 | -0.140575 | -0.95 |
Immunocore Holdings Earnings History
Earnings estimate consensus by Immunocore Holdings analysts from Wall Street is used by the market to judge Immunocore Holdings' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Immunocore Holdings' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Immunocore Holdings Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immunocore Holdings' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Immunocore Holdings Earnings per Share Projection vs Actual
Actual Earning per Share of Immunocore Holdings refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Immunocore Holdings predict the company's earnings will be in the future. The higher the earnings per share of Immunocore Holdings, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Immunocore Holdings Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Immunocore Holdings, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Immunocore Holdings should always be considered in relation to other companies to make a more educated investment decision.Immunocore Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Immunocore Holdings' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-05-06 | 2025-03-31 | -0.36 | -0.49 | -0.13 | 36 | ||
2024-11-05 | 2024-09-30 | -0.35 | 0.17 | 0.52 | 148 | ||
2024-08-08 | 2024-06-30 | -0.48 | -0.23 | 0.25 | 52 | ||
2024-05-08 | 2024-03-31 | -0.36 | -0.49 | -0.13 | 36 | ||
2024-02-28 | 2023-12-31 | -21.74 | -32.22 | -10.48 | 48 | ||
2023-11-07 | 2023-09-30 | -28.92 | 4.0 | 32.92 | 113 | ||
2023-08-10 | 2023-06-30 | -32.1 | -0.37 | 31.73 | 98 | ||
2023-05-10 | 2023-03-31 | -32.19 | -35.0 | -2.81 | 8 | ||
2023-03-01 | 2022-12-31 | 0.03 | -54.0 | -54.03 | 180100 | ||
2022-11-09 | 2022-09-30 | -29.01 | 12.0 | 41.01 | 141 | ||
2022-08-10 | 2022-06-30 | -68.48 | -14.0 | 54.48 | 79 | ||
2022-05-11 | 2022-03-31 | -85.74 | -37.0 | 48.74 | 56 | ||
2022-03-03 | 2021-12-31 | -82.21 | -91.0 | -8.79 | 10 | ||
2021-11-10 | 2021-09-30 | -0.85 | -0.93 | -0.08 | 9 | ||
2021-08-11 | 2021-06-30 | -0.95 | -1.04 | -0.09 | 9 | ||
2021-05-12 | 2021-03-31 | -0.83 | -0.92 | -0.09 | 10 | ||
2021-03-25 | 2020-12-31 | -1.05 | -0.82 | 0.23 | 21 | ||
2020-09-30 | 2020-06-30 | 0 | -0.0041 | -0.0041 | 0 | ||
2020-06-30 | 2020-03-31 | 0 | -0.0043 | -0.0043 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.0043 | -0.0043 | 0 | ||
2019-12-31 | 2019-09-30 | 0 | -13.6714 | -13.6714 | 0 | ||
2019-09-30 | 2019-06-30 | 0 | -0.0074 | -0.0074 | 0 | ||
2019-06-30 | 2019-03-31 | 0 | -0.0077 | -0.0077 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | -0.0079 | -0.0079 | 0 |
About Immunocore Holdings Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Immunocore Holdings earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Immunocore Holdings estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Immunocore Holdings fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -670.2 M | -636.7 M | |
| Earnings Yield | (0.01) | (0.02) | |
| Price Earnings Ratio | (69.48) | (66.00) | |
| Price Earnings To Growth Ratio | (2.72) | (2.58) |
Pair Trading with Immunocore Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.Moving together with Immunocore Stock
| 0.77 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Immunocore Stock
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.